Overview

Preoxygenation With Optiflow™ in Morbidly Obese Patients is Superior to Face Mask

Status:
Withdrawn
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Optiflow™ may provide an opportunity to prolong apnea time in the morbidly obese patient population. This study will examine whether Optiflow can do this, and compare the pre-oxygenation with Optiflow to the pre-oxygenation achieved with face mask.
Phase:
N/A
Details
Lead Sponsor:
Montefiore Medical Center
Collaborators:
M.D. Anderson Cancer Center
The University of Texas Health Science Center, Houston
Treatments:
Fentanyl
Midazolam
Propofol
Rocuronium